International Journal of Pharmaceutics 2013-09-15

II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.

Lauretta Maggi, Giovanna Bruni, Mariarosa Maietta, Andrea Canobbio, Andrea Cardini, Ubaldo Conte

文献索引:Int. J. Pharm. 454(1) , 568-72, (2013)

全文:HTML全文

摘要

Nateglinide is an oral antidiabetic agent that should be administered 10-30 min before the meal, but it shows low and pH-dependent solubility that may reduce its oral bioavailability. To improve nateglinide dissolution rate, the active was co-milled with three different super-disintegrants or with some hydrophilic excipients, in 1:1, 1:2, and 1:4 drug to carrier ratio (w:w). The three super-disintegrants were crosslinked polyvinylpyrrolidone (PVPC), sodium starch glycolate (SSG) and crosslinked carboxymethyl cellulose (CMCC). The three hydrophilic excipient were amorphous silica (AS), mannitol (M) and Poloxamer (PO). A strong enhancement of drug dissolution rate was obtained from the nateglinide:super-disintegrant co-milled systems in 1:4 ratio, which can be explained by a combination of several factors: an increase in wettability, due to the hydrophilic nature of the carriers, a possible reduction of particle size and a more intimate dispersion of the drug onto the carrier, as a result of the mechanical treatment.Copyright © 2013 Elsevier B.V. All rights reserved.


相关化合物

  • 那格列奈
  • 聚乙烯吡咯烷酮
  • 甘露醇
  • 羧甲基纤维素钠
  • 那格列奈相关物质C
  • 羧甲基淀粉钠

相关文献:

Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.

2013-11-01

[Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)]

From evidence assessments to coverage decisions?: the case example of glinides in Germany.

2012-01-01

[Health Policy 104(1) , 27-31, (2012)]

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

2005-10-01

[Int. J. Clin. Pract. 59(10) , 1218-28, (2005)]

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.

2012-02-01

[Diabetes Obes. Metab. 14(2) , 187-9, (2012)]

Nateglinide (Starlix): update on a new antidiabetic agent.

2003-01-01

[Int. J. Clin. Pract. 57(6) , 535-41, (2003)]

更多文献...